Its funny about Biomed value. Something has to happen to small promising Bio-meds before they transition from next to no value to massive value. Jason Napodano says for AMBS it is money. Once we have enough money that we can move LymPro and several MANF indications forward without needing Big Pharma Partnership money...the more value we become to Big Pharma. It's the "forbidden fruit" thing, you always want what you can't get. The harder to get Gerald is able to play, the more intensely Big Pharma will pursue him. I think Gerald is benefited by having some powerful people with a lot of experience around him giving him coaching. They know the way to the "Promised Land."